IDEXX Laboratories, Inc. (IDXX)
Animal Health Firm Idexx's Robust Business Model Bolsters Position Despite Slower Growth, Says Analyst
Tuesday, Idexx Laboratories Inc IDXX reported second-quarter adjusted EPS of $3.02, up 15% year-over-year, beating the consensus of $2.88.
IDEXX Laboratories, Inc. (IDXX) Q2 2024 Earnings Call Transcript
IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - President and CEO Conference Call Participants Chris Schott - JPMorgan Michael Ryskin - Bank of America Erin Wright - Morgan Stanley Jonathan Block - Stifel David Westenberg - Piper Sandler Operator Good morning, and welcome to the IDEXX Laboratories Second Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded.
IDEXX (IDXX) Q2 Earnings Miss Estimates, 2024 View Down
IDEXX's (IDXX) Q2 earnings miss estimates but revenues meet the same.
Idexx (IDXX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Idexx Laboratories (IDXX) Lags Q2 Earnings Estimates
Idexx Laboratories (IDXX) came out with quarterly earnings of $2.44 per share, missing the Zacks Consensus Estimate of $2.87 per share. This compares to earnings of $2.67 per share a year ago.
Unlocking Q2 Potential of Idexx (IDXX): Exploring Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Idexx (IDXX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strong CAG Sales to Aid IDEXX Laboratories' (IDXX) Q2 Earnings
IDEXX Laboratories' (IDXX) second-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.
Looking For Fast Growth In Healthcare? IDEXX Has You Covered
IDEXX Laboratories is a $41 billion market cap giant in the diagnostics and research industry, with shares falling 13% since February. The company specializes in animal healthcare diagnostics, showing rapid growth and innovation in a high-growth market. Despite a lofty valuation, IDEXX's strong financials, consistent revenue growth, and long-term growth prospects justify a Buy rating.
IDEXX (IDXX) Business Faces Macroeconomic Woes, FX Headwinds
IDEXX's (IDXX) supply chain operations bear the brunt of geopolitical instability, including the current war in Ukraine.
IDEXX (IDXX) Expands Test Menu for the Catalyst Platform
IDEXX's (IDXX) new Catalyst Pancreatic Lipase Test is likely to support veterinarians globally in diagnosing pancreatitis.
Why Is Idexx (IDXX) Up 5% Since Last Earnings Report?
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?
